Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/204935
Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) pa- tient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal telangiectasia is one of the major involvements that can produce chronic severe iron-deficiency anemia. Nowadays, support treatment with iron replacement therapy, red blood cell transfusions, and antiangiogenic drugs—mainly bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)—are the main therapeutic options for this complication. The evidence of alternative drugs in patients with failure to this approach, such as tachyphylaxis to bevacizumab, is scarce. Aflibercept is a VEGF inhibitor with antiangiogenic properties approved for the treatment of different types of cancer and ocular neovascularization diseases.
Matèries
Matèries (anglès)
Citació
Citació
VILLANUEVA, Bernat, IRIARTE, Adriana, TORRES IGLESIAS, Raquel, MUÑOZ BOLAÑO, Miriam, CERDÀ, Pau, RIERA MESTRE, Antoni. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.. _Medicina (Kaunas)_. 2023. Vol. 59, núm. 9. [consulta: 23 de gener de 2026]. ISSN: 1010-660X. [Disponible a: https://hdl.handle.net/2445/204935]